Statins May Reduce Risk for HCC in Hep B-Infected Patients

StephenW

http://www.doctorslounge.com/index.php/news/pb/26179
Statins May Reduce Risk for HCC in Hep B-Infected Patients
Last Updated: January 23, 2012.

For hepatitis B virus-infected patients, statin use is associated with a reduction in the risk for hepatocellular carcinoma, in a dose-dependent manner, according to a study published online Jan. 23 in the Journal of Clinical Oncology.MONDAY, Jan. 23 (HealthDay News) -- For hepatitis B virus (HBV)-infected patients, statin use is associated with a reduction in the risk for hepatocellular carcinoma (HCC), in a dose-dependent manner, according to a study published online Jan. 23 in the Journal of Clinical Oncology.
Yu-Tse Tsan, from the National Taiwan University College of Public Health in Taipei, and colleagues analyzed data from 33,413 HBV-infected patients from the Taiwan National Health Insurance Research Database to investigate the association between statin use and HCC risk. Patients were tracked individually from 1997 to 2008 to detect incident cases of HCC since 1999. The use of statins, other lipid-lowering agents, aspirin, and angiotensin-converting enzyme inhibitors was examined.
Over 328,946 person-years of follow-up, the researchers identified 1,021 HCCs in the HBV cohort, representing an incidence rate of 310.4 HCCs per 100,000 person-years. There was a dose-response association between statin use and the risk of HCC. Compared with no statin use (less than 28 cumulative defined daily doses [cDDD]), the adjusted hazard ratios were 0.66 for statin use of 28 to 90 cDDDs, 0.41 for 91 to 365 cDDDs, and 0.34 for more than 365 cDDDs.
"Statin use may reduce the risk for HCC in HBV-infected patients in a dose-dependent manner," the authors write.




(6.合.彩)足球.篮球...各类投注开户下注

第一投注现金网:招代理年薪10万以上:yyu.cc

StephenW

他汀类药物可降低肝癌的乙肝感染患者的风险
最后更新：2012年1月23日。

  

    在B型肝炎感染的患者的剂量依赖性降低肝癌风险

B型肝炎病毒感染的患者，他汀类药物的使用在剂量依赖的方式，与肝癌的风险降低相关联，根据一项研究发表在“临床肿瘤学杂志”1月23日在网上。

1月23日（健康新闻） - B型肝炎病毒（HBV）感染的患者，他汀类药物的使用是与在肝细胞癌（HCC）的风险降低，在剂量依赖的方式，根据一项研究1月23日在线发表在临床肿瘤学杂志。

于谢赞，国立台湾大学公共卫生学院在台北，和他的同事分析了从台湾国民健康保险研究资料库，以探讨他汀类药物的使用和肝癌风险之间的关联，从33413 HBV感染患者的数据。患者分别从1997年至2008年进行了跟踪检测自1999年以来肝癌病例。使用的他汀类药物，其他降脂药物，阿司匹林，血管紧张素转换酶抑制剂的研究。

超过328946人 - 年的随访中，研究人员发现在HBV队列1021肝癌，即每十万人年的310.4肝癌的发病率。是他汀类药物的使用和肝癌风险之间的剂量 - 反应的关联。没有使用他汀类药物（累计不少于28[cDDD]每天服用）相比，调整后的危险比分别为0.66为28日至90 cDDDs，为91至365 cDDDs0.41和0.34的他汀类药物的使用超过365 cDDDs。

“他汀类药物的使用可能会降低肝癌的乙肝病毒感染的患者，在剂量依赖性的风险，”作者写道。

咬牙硬挺

史蒂芬新年快乐！在国外也过春节吗

StephenW

回复 咬牙硬挺 的帖子

哪里有中国人，
那里有庆祝活动. 我们有特殊的客人从成都来帮助我们一起庆祝。

StephenW

Statins may prevent hepatitis from progressing to liver cancer  

Updated: 2012-01-27 17:04:15 CST Category: Liver Diseases

Individuals who have received liver panel test results indicating they have hepatitis B may benefit from a prescription for statin medications. New research suggests that these drugs may prevent their condition from progressing to liver cancer.

Hepatitis infection is one of the leading causes of liver cancer, which can be particularly dangerous. Yet, little is known about how to prevent the damage associated with hepatitis that often leads to liver cancer.

For the present study, researchers from the National Taiwan University analyzed the medical records of more than 33,000 individuals treated for hepatitis B between 1997 and 2008. The results showed that those who were taking statins were significantly less likely to develop liver cancer.

The researchers said that further investigation is needed to understand how statins may reduce liver cancer risk, but that their findings could represent a simple and effective way to improve the health of individuals with hepatitis B. This may lead to improved liver panel tests for individuals with the infectious disease.

他汀类药物可能会阻止进展为肝癌肝炎

更新时间：2012年1月27日17时04分15秒CST类别：肝病

他汀类药物可以防止肝炎进展为肝癌肝功能试验结果表明他们有B型肝炎可能会受益于他汀类药物的处方的个人收到。新的研究表明，这些药物可能会阻止他们的病情发展到肝癌。

肝炎感染是肝癌的主要原因，它可以是特别危险的之一。然而，鲜为人知的是如何防止肝炎相关的损害，往往会导致肝癌。

对于目前的研究中，来自台湾国立大学的研究人员分析了超过33,000个人在1997年和2008年之间为B型肝炎治疗的医疗记录。结果表明，那些服用他汀类药物显著不太可能发展肝癌。

研究人员说，需要进一步调查，以了解他汀类药物可能会降低肝癌的风险，但他们的研究结果可以代表一个简单而有效的方式，以改善个人与B型肝炎的健康，这可能会导致改善肝个人面板测试传染病。 ADNFCR- 2248- ID -800694878- ADNFCR